GSK-NIAID Ebola vaccine arrives in Liberia; awaits trial
This article was originally published in Scrip
Executive Summary
A day after US officials said they were putting the finishing touches on preparations to launch a Phase II/III trial testing two experimental Ebola vaccines in Liberia, GlaxoSmithKline, which co-developed one of those products, shipped 300 vials of its chimpanzee adenovirus type 3 (ChAd3) candidate to study sites in the West African country.